ClinicalTrials.gg
Active, not recruitingNCT06015672Updated Oct 26, 2026

Accelerated TMS for Focal Hand Dystonia

An interventional study of Transcranial Magnetic Stimulation (TMS) in Isolated Focal Hand Dystonia, sponsored by Duke University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 26, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Dystonia, Focal, Task-Specific with a site in United States — 1 open to participants now, 3 under way, none of them phase 3. Dystonia, Focal, Task-Specific · United States.

Started
2023
the only one that year
No phase
3 of 21
1 open now
Registered
19th of 21
by date
Lead sponsor
2 of 21
Duke University

Among the 21 studies in Dystonia, Focal, Task-Specific with a site in United States, this one is the only one that started in 2023, is one of 3 with no phase, and was the 19th registered.

Dystonia, Focal, Task-Specific

26 studies on the registry are indexed under Dystonia, Focal, Task-Specific; 3 are open to participants now.

Browse Dystonia, Focal, Task-Specific studies →

Open to participants now

1 of the 21 studies in Dystonia, Focal, Task-Specific with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Dystonia, Focal, Task-Specific studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Dystonia, Focal, Task-Specific with a site in United States, or all of them as a file.
02

Study summary

This study aims to investigate the impact of accelerated transcranial magnetic stimulation (TMS) on brain function and behavior in patients with focal hand dystonia. Previous research demonstrated that individualized TMS improved dystonic behavior after one session. Building on this, the current study administers four TMS sessions in a day, with assessments conducted in four weeks, twelve weeks, and 20 weeks after each session. The research involves 8 in-person and 6 virtual visits focused on functional MRI brain scans and writing behavior analysis. The potential risk of seizures from TMS is mitigated through careful screening, adhering to safety guidelines. The study's main benefit is enhancing dystonic behavior and deepening the understanding of brain changes caused by TMS in focal hand dystonia, paving the way for further advancements in clinical therapy for this condition.

Read the detailed description

The primary aim of this research is to investigate the impact of transcranial magnetic stimulation (TMS) on both brain function and behavioral outcomes among individuals suffering from focal hand dystonia. A preliminary examination of a previous TMS study carried out by our team revealed that the application of TMS, using personalized, fMRI-guided brain targeting and interleaved TMS delivery during motor tasks, has the potential to modify brain activity and ameliorate dystonic behavior after a single session of TMS in patients with focal hand dystonia. This present study seeks to build upon these promising findings by administering four TMS sessions in a single day, interspersed with four rest intervals, a protocol referred to as "accelerated TMS." The investigation will consist of a total of eight in-person appointments. Participants with focal hand dystonia will receive accelerated TMS during two in-person visits. Following each TMS session, participants will evaluate changes in brain function and behavior. During the assessment visits, individuals will undergo functional MRI brain scans and engage in writing tasks on an electronic tablet. The principal risk associated with TMS is the possibility of inducing a seizure. However, this study will strictly adhere to safety guidelines, utilizing TMS levels that have not previously been linked to seizures in properly screened individuals. Notably, the dosages of TMS proposed for use in this study have not caused seizures in healthy volunteers. To further mitigate the risk of seizures, potential subjects will undergo medical screening for any known factors that could predispose them to seizures. The primary advantage of this study lies in its potential to enhance dystonic behavior in patients with focal hand dystonia, while also deepening our comprehension of the foundational changes in brain function before and after TMS intervention for focal hand dystonia. The discoveries stemming from this investigation will pave the way for future research endeavors aimed at advancing brain stimulation as a viable clinical therapy for focal hand dystonia.

03

Conditions studied

  • Isolated Focal Hand Dystonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18yrs and older
  • Diagnosed with isolated focal hand by Neurologist
  • Right-hand dominant
  • Must be able to sign an
  • Must be literate

Exclusion criteria

Exclusion Criteria:

  • Other neurological movement disorders diagnoses including other types of dystonia, Parkinsonism, or essential tremor
  • History of seizure disorder
  • Concomitant medications are known to decrease seizure threshold
  • Illicit drug use
  • No TMS therapy for another indication within one month of this research study
  • Botulinum toxin injections within 3months of the research study
  • Medications used for symptom treatment of dystonia including anticholinergic, benzodiazepines, and muscle relaxants among others within one month of the study
  • No physical or occupational therapy of the hand within one month of the study
  • Any to MRI or TMS
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Active comparator
    TMS to primary somatosensory cortex

    Participants received TMS sessions at primary somatosensory cortex

    Device: Transcranial Magnetic Stimulation (TMS)

  • Sham comparator
    TMS at low amplitude to primary somatosensory cortex

    Participants receive TMS at a cortical target at smaller amplitude

    Device: Transcranial Magnetic Stimulation (TMS)

Interventions

  • DeviceTranscranial Magnetic Stimulation (TMS)

    Participants will have two accelerated transcranial magnetic stimulation (TMS) visits. Each TMS visit will be separated by 5 months. During each TMS visit, they will receive four TMS sessions, each separated by 60 minutes of rest.

06

What researchers measure

Primary outcomes

  1. Measurement of Hand Sensation using STDT

    Surface skin electrodes will be placed on the index finger of the right hand of the participant. The anode will be located 0.5 cm distal to the cathode. The surface electrodes will be connected by a wire to a constant current stimulator. Participants will receive a stimulus consisting of a square-wave electrical pulse with a width of 0.2 milliseconds delivered with a constant current stimulator. A stimulation intensity will first be defined for each participant by delivering a series of stimuli at increasing intensity from 2 mA in steps of 1 mA; the intensity used for STDT will be the minimal intensity perceived by the participant in 10 of 10 consecutive stimuli. STDT will then be investigated using an ascending staircase method. Specifically, paired stimuli will be delivered to the anode and cathode skin electrodes attached to the participant's right-hand digit. The paired stimuli will be delivered starting with an interstimulus

    Time frame: Baseline, 4 weeks, 12 weeks, 20 weeks, 24, weeks, 32 weeks and 40 weeks

Secondary outcomes

  1. Change in behavioral writing measure

    Using change in peak accelerations to assess writing behavior

    Time frame: Baseline, 4 weeks, 12 weeks, 20 weeks, 24, weeks, 32 weeks and 40 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Noreen Bukhari-Parlakturk, Patrick Mulcahey, Michael Lutz, Rabia Ghazi, Ziping Huang, Moritz Dannhauer, Zeynep Simsek, Skylar Groves, Mikaela Lipp, Michael Fei, Tiffany Tran, Eleanor Wood, Lysianne Beynel, Burton Scott, Pichet Termsarasab, Chris Petty, Hussein R Al-Khalidi, James Voyvodic, Lawrence G. Appelbaum, Simon Davis, Andrew Michael, Angel Peterchev, Nicole Calakos. "Functional MRI-guided individualized TMS modifies motor network and reduces writing dysfluency in Focal Hand Dystonia." Human Brain Mapping Conference. Montreal, Canada. July 22-26, 2023. virtual poster presentation.
  • Noreen Bukhari-Parlakturk, Patrick Mulcahey, Michael Lutz, Rabia Ghazi, Ziping Huang, Moritz Dannhauer, Zeynep Simsek, Skylar Groves, Mikaela Lipp, Michael Fei, Tiffany Tran, Eleanor Wood, Lysianne Beynel, Burton Scott, Pichet Termsarasab, Chris Petty, Hussein R Al-Khalidi, James Voyvodic, Lawrence G. Appelbaum, Simon Davis, Andrew Michael, Angel Peterchev, Nicole Calakos. "Functional MRI-guided individualized TMS modifies motor network and reduces writing dysfluency in Focal Hand Dystonia." Samuel Belzberg 6th International Dystonia Symposium. Dublin, Ireland. June 1-3, 2023. poster presentation.
  • Bukhari-Parlakturk N, Lutz MW, Al-Khalidi HR, Unnithan S, Wang JE, Scott B, Termsarasab P, Appelbaum LG, Calakos N. Suitability of Automated Writing Measures for Clinical Trial Outcome in Writer's Cramp. Mov Disord. 2023 Jan;38(1):123-132. doi: 10.1002/mds.29237. Epub 2022 Oct 13. PubMed 36226903 ↗
  • Dannhauer M, Huang Z, Beynel L, Wood E, Bukhari-Parlakturk N, Peterchev AV. TAP: targeting and analysis pipeline for optimization and verification of coil placement in transcranial magnetic stimulation. J Neural Eng. 2022 Apr 21;19(2):10.1088/1741-2552/ac63a4. doi: 10.1088/1741-2552/ac63a4. PubMed 35377345 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Feb 2027, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Aug 29, 2023
StartActual
Dec 21, 2023
Primary completionEst.
Feb 5, 2027
CompletionEst.
Feb 5, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedMeasurement of Hand Sensation using STDTTime frame: Baseline, 4 weeks, 12 weeks, 20 weeks, 24, weeks, 32 weeks and 40 weeks
  • RemovedChange in behavioral writing measureTime frame: Baseline, 4 weeks, 12 weeks, 20 weeks, 24, weeks, 32 weeks and 40 weeks
  • RemovedChange in brain connectivity in the motor networkTime frame: Baseline, 12 weeks, 20 weeks and 32 weeks
Oct 26, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedChange in behavioral writing measureTime frame: Baseline, 4 weeks, 12 weeks, 20 weeks, 24, weeks, 32 weeks and 40 weeks
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedMeasurement of Hand Sensation using STDTTime frame: Baseline, 4 weeks, 12 weeks, 20 weeks, 24, weeks, 32 weeks and 40 weeks
    • RemovedChange in behavioral writing measureTime frame: Baseline, 4 weeks, 12 weeks, 20 weeks, 24, weeks, 32 weeks and 40 weeks
    • RemovedChange in brain connectivity in the motor networkTime frame: Baseline, 12 weeks, 20 weeks and 32 weeks
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedChange in behavioral writing measureTime frame: Baseline, 4 weeks, 12 weeks, 20 weeks, 24, weeks, 32 weeks and 40 weeks

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06015672
Lead sponsor
Duke University
Collaborators
American Academy of Neurology
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Dec 21, 2023
Primary completion
Feb 5, 2027 (estimated)
Completion
Feb 5, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Noreen Bukhari-Parlakturk, MD PhD
principal investigator · Duke Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion